File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Fosinopril reduces left ventricular mass in untreated hypertensive patients: A controlled trial

TitleFosinopril reduces left ventricular mass in untreated hypertensive patients: A controlled trial
Authors
KeywordsAngiotensin-converting enzyme inhibitors
Fosinopril
Hypertension
Left ventricular hypertrophy
Issue Date1999
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCP
Citation
British Journal Of Clinical Pharmacology, 1999, v. 47 n. 2, p. 179-187 How to Cite?
AbstractAims. Left ventricular hypertrophy is a powerful predictor of cardiovascular morbidity and mortality. We tested the hypothesis that fosinopril, an angiotensin-converting enzyme inhibitor, reduces left Ventricular mass in hypertensive patients. Methods. Thirty-three patients with untreated mild essential hypertension were randomised to treatment with oral fosinopril (10 mg-20 mg daily) or placebo for 12 weeks. The primary outcome measure was the change in left ventricular mass index determined by echocardiography. Results. Diastolic blood pressure changed from 95.5 ± 2.1 mmHg at baseline to 96.6 ± 2.8 mmHg at the final visit in control patients and changed from 96.6 ± 2.3 mmHg to 91.5 ± 3.0 mmHg in patients treated with fosinopril (P = 0.04). Systolic blood pressure changed from 147.4 ± 3.2 mmHg at baseline to 152.7 ± 4.4 mmHg at the final visit in control patients and changed from 157.6 ± 5.1 mmHg to 149.1 ± 6.1 mmHg in patients treated with fosinopril (P 0.02). Fosinopril reduced diastolic pressure by 6.3 (95% CI 0.3-12.4) mmHg and systolic pressure by 13.3 (95% CI 2.7-23.8) mmHg compared with placebo. The left ventricular mass index changed from 110.0 ± 8.3 g m-2 to 113.1 ± 8.7 g m-2 in the control patients and changed from 120.8 ± 5.8 g m-2 to 109.0 ± 7.5 g m-2 in patients treated with fosinopril (P = 0.02). Fosinopril reduced left ventricular mass index by 14.9 (95% CI 2.2-27.6) g m-2 compared with placebo. There was no significant change in the left ventricular systolic or diastolic function, nor were there any significant changes in plasma electrolytes and renal function. Conclusions. Treatment with fosinopril for 12 weeks reduced left ventricular mass significantly in hypertensive patients.
Persistent Identifierhttp://hdl.handle.net/10722/49097
ISSN
2015 Impact Factor: 3.83
2015 SCImago Journal Rankings: 1.486
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, BMYen_HK
dc.contributor.authorLau, CPen_HK
dc.date.accessioned2008-06-12T06:34:21Z-
dc.date.available2008-06-12T06:34:21Z-
dc.date.issued1999en_HK
dc.identifier.citationBritish Journal Of Clinical Pharmacology, 1999, v. 47 n. 2, p. 179-187en_HK
dc.identifier.issn0306-5251en_HK
dc.identifier.urihttp://hdl.handle.net/10722/49097-
dc.description.abstractAims. Left ventricular hypertrophy is a powerful predictor of cardiovascular morbidity and mortality. We tested the hypothesis that fosinopril, an angiotensin-converting enzyme inhibitor, reduces left Ventricular mass in hypertensive patients. Methods. Thirty-three patients with untreated mild essential hypertension were randomised to treatment with oral fosinopril (10 mg-20 mg daily) or placebo for 12 weeks. The primary outcome measure was the change in left ventricular mass index determined by echocardiography. Results. Diastolic blood pressure changed from 95.5 ± 2.1 mmHg at baseline to 96.6 ± 2.8 mmHg at the final visit in control patients and changed from 96.6 ± 2.3 mmHg to 91.5 ± 3.0 mmHg in patients treated with fosinopril (P = 0.04). Systolic blood pressure changed from 147.4 ± 3.2 mmHg at baseline to 152.7 ± 4.4 mmHg at the final visit in control patients and changed from 157.6 ± 5.1 mmHg to 149.1 ± 6.1 mmHg in patients treated with fosinopril (P 0.02). Fosinopril reduced diastolic pressure by 6.3 (95% CI 0.3-12.4) mmHg and systolic pressure by 13.3 (95% CI 2.7-23.8) mmHg compared with placebo. The left ventricular mass index changed from 110.0 ± 8.3 g m-2 to 113.1 ± 8.7 g m-2 in the control patients and changed from 120.8 ± 5.8 g m-2 to 109.0 ± 7.5 g m-2 in patients treated with fosinopril (P = 0.02). Fosinopril reduced left ventricular mass index by 14.9 (95% CI 2.2-27.6) g m-2 compared with placebo. There was no significant change in the left ventricular systolic or diastolic function, nor were there any significant changes in plasma electrolytes and renal function. Conclusions. Treatment with fosinopril for 12 weeks reduced left ventricular mass significantly in hypertensive patients.en_HK
dc.format.extent388 bytes-
dc.format.mimetypetext/html-
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCPen_HK
dc.relation.ispartofBritish Journal of Clinical Pharmacologyen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsBritish Journal of Clinical Pharmacology. Copyright © Blackwell Publishing Ltd.en_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.comen_HK
dc.subjectAngiotensin-converting enzyme inhibitorsen_HK
dc.subjectFosinoprilen_HK
dc.subjectHypertensionen_HK
dc.subjectLeft ventricular hypertrophyen_HK
dc.titleFosinopril reduces left ventricular mass in untreated hypertensive patients: A controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0306-5251&volume=47&issue=2&spage=179&epage=187&date=1999&atitle=Fosinopril+reduces+left+ventricular+mass+in+untreated+hypertensive+patients:+a+controlled+trialen_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1046/j.1365-2125.1999.00873.xen_HK
dc.identifier.pmid10190653-
dc.identifier.pmcidPMC2014174en_HK
dc.identifier.scopuseid_2-s2.0-0033064444en_HK
dc.identifier.hkuros42723-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033064444&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume47en_HK
dc.identifier.issue2en_HK
dc.identifier.spage179en_HK
dc.identifier.epage187en_HK
dc.identifier.isiWOS:000078676700008-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK
dc.identifier.scopusauthoridLau, CP=7401968501en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats